Anticoagulation Options for Patients with Permanent Pacemakers

Risk Assessment and Anticoagulation Decision-Making

The American College of Cardiology recommends that the need for anticoagulation in patients with pacemakers should be determined by the underlying condition requiring anticoagulation, not the presence of the pacemaker itself 1, 3
For patients with atrial fibrillation, the CHA₂DS₂-VASc score should be used to assess stroke risk and guide anticoagulation decisions, as recommended by the American College of Cardiology 1, 2
Anticoagulation is recommended for men with a CHA₂DS₂-VASc score ≥2 or women with a score ≥3, according to the American College of Cardiology guidelines 1, 3

The American College of Cardiology recommends direct oral anticoagulants (DOACs) as first-line therapy for most patients, with a Class I, Level of Evidence: A recommendation 1, 2
Apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients) is a recommended DOAC option, as suggested by the American College of Cardiology and Circulation 1, 4
Dabigatran 150 mg twice daily (or 110 mg twice daily in selected patients) is a recommended DOAC option, according to the American College of Cardiology and Circulation 1, 4
Rivaroxaban 20 mg once daily (or 15 mg once daily in selected patients) is a recommended DOAC option, as recommended by the American College of Cardiology and Circulation 1, 4
Edoxaban 60 mg once daily (or 30 mg once daily in selected patients) is a recommended DOAC option, according to the American College of Cardiology and Circulation 1, 4
Warfarin is an alternative option, with a target INR 2.0-3.0 and monitoring at least weekly during initiation and at least monthly when stable, as recommended by the American College of Cardiology 1, 3

The American College of Cardiology recommends Warfarin as the only option for patients with mechanical heart valves, with a Class I, Level of Evidence: B recommendation 1
For patients with moderate-to-severe mitral stenosis, Warfarin is recommended, according to the American College of Cardiology guidelines 1, 2

For patients requiring both anticoagulation and antiplatelet therapy, double therapy (DOAC plus P2Y12 inhibitor) is preferred over triple therapy for most patients after hospital discharge, as recommended by Circulation 5, 6
Renal function should be evaluated before initiating a DOAC and at least annually thereafter, as dose adjustments may be required, according to the American College of Cardiology and European Heart Journal 1, 7